Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NicOx Adds Two Blood Pressure Monitoring Studies To Naproxcinod Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Results of both blood pressure studies and two Phase III trials expected in 2008, positioning naproxcinod for mid-2009 filing.

You may also be interested in...



Naproxcinod Can Win Approval Without Superiority Trial, NicOx Says

Facing skeptical FDA, company in partnering talks as more Phase III data with anti-inflammatory drug prove positive.

Naproxcinod Can Win Approval Without Superiority Trial, NicOx Says

Facing skeptical FDA, company in partnering talks as more Phase III data with anti-inflammatory drug prove positive.

NicOx Gets Positive Results In Second Phase III Trial For Naproxcinod

In addition to meeting clinical endpoints, anti-inflammatory continues to show non-detrimental effect on blood pressure.

Related Content

Topics

UsernamePublicRestriction

Register

PS067499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel